9α-Fluorpregn-4-en-11β,17α,21-triol-3,20-dion-11-acetat | 16376-32-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 9α-Fluorpregn-4-en-11β,17α,21-triol-3,20-dion-11-acetat
• 英文别名: [(8S,9R,10S,11S,13S,14S,17R)-9-fluoro-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-11-yl] acetate
• CAS: 16376-32-2
• 化学式: C₂₃H₃₁FO₆
• 分子量: 422.494
• InChiKey: WDUYGQVAOZUREO-CQETUWSJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Anti-scarring drug combinations and use thereof
  申请人：Hunter L. William

  公开号：US20070208134A1

  公开（公告）日：2007-09-06

  The present invention provides devices or implants that comprise anti-scarring drug combinations, methods or making such devices or implants, and methods of inhibiting fibrosis between the devices or implants and tissue surrounding the devices or implants. The present invention also provides compositions that comprise anti-fibrotic drug combinations, and their uses in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.
• Electrical devices and anti-scarring drug combinations
  申请人：Hunter L. William

  公开号：US20070198063A1

  公开（公告）日：2007-08-23

  Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring drug combination or a composition that comprises an anti-scarring drug combination to inhibit scarring that may otherwise occur when the devices are implanted within an animal.